Globus Medical Inc-A 2024年度报告

xANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934For the fiscal year endedDecember31, 2024or¨TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934For the transition period from ______________ to _______________ Commission File No.001-35621 GLOBUS MEDICAL, INC.(Exact name of registrant as specified in its charter) DELAWARE04-3744954(State or other jurisdiction of incorporation or organization)(I.R.S. Employer Identification No.) 2560 General Armistead Avenue,Audubon,PA19403(610)930-1800(Address of principal executive offices) (Zip Code)(Registrant’s telephone number, including Area Code) Securities registered pursuant to Section 12(b) of the Act:Trading Symbol(s)Name of exchange on which registered Title of each classClass A Common Stock, par value $.001 per shareGMEDNew York Stock Exchange Securities registered pursuant to Section 12(g) of the Act:None Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act: YesxNo¨ Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act: Yes¨Nox Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to suchfiling requirements for the past 90 days: Yesx No¨ Indicate by check mark whether the registrant has submitted electronically, every Interactive Data File required to be submitted pursuant to Rule 405of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submitsuch files): YesxNo¨ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company oran emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growthcompany” in Rule 12b-2 of the Exchange Act:Large Accelerated Filerx Accelerated Filer¨Non-accelerated Filer¨Smaller Reporting Company¨Emerging Growth Company¨ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying withany new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.oIndicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment ofthe effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C.7262(b)) by the registered public accounting firm that prepared or issued its audit report.x If securities are registered pursuant to Section 12(b) of the Exchange Act, indicate by check mark whether the financial statements of theregistrant included in the filing reflect the correction of an error to previously issued financial statements.☐ Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensationreceived by any of the registrant’s executive officers during the relevant recovery period pursuant to §240.10D-1(b).☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act): Yes¨Nox The aggregate market value of the voting and non-voting common equity held by non-affiliates of the registrant, computed by reference to the closingsales price for the registrant’s common stock on the last business day of the registrant’s most recently completed second quarter, June30, 2024, asreported on the New York Stock Exchange, was approximately $7.7billion. Table of Contents The number of shares outstanding of the issuer’s common stock (par value $0.001 per share) as of February18, 2025 was137,541,648shares. DOCUMENTS INCORPORATED BY REFERENCE Portions of our Proxy Statement for our 2025 Annual Meeting of Stockholders, to be filed within 120 days of December31, 2024, are incorporated byreference in Part III, Items 10, 11, 12, 13 and 14 herein of this Annual Report. Such Proxy Statement, except for the parts therein which have beenspecifically incorporated by reference, shall not be deemed “filed” for the purposes of this Annual Report on Form 10-K. GLOBUS MEDICAL, INC. AND SUBSIDIARIESTABLE OF CONTENTS PART IBusiness Item 1.5Item1A.Risk Factors20Item1B.Unresolved Staff Comments46Item 1C.Cybersecurity Risk Management, Strategy, Governance, and Incident Disclosure46Item 2.Properties46Item 3.Legal Proceedings46Item 4.Mine Safety Disclosures47 PART IIItem 5.Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of EquitySecurities48Item 7.Management’s Discussion and Analys